



ON THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stephen ARKINSTALL, et al.

Application No.: 10/070,954

Filed: July 22, 2002

For: PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES

Art Unit: 1624

Examiner: Brenda L. Coleman

Washington, D.C.

Atty.'s Docket: ARKINSTALL=1

Date: April 11, 2007

Confirmation No. 4903

THE COMMISSIONER OF PATENTS
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop AF
401 Dulany Street
Alexandria, VA 22314

Sir:

Transmitted herewith is a [XX] REPLY: AMENDMENT AND REMARKS in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NO. PREVIOUSLY PAID FOR	(Col. 3) PRESENT EXTRA EQUALS
TOTAL	* 21	MINUS	** 43	0
INDEP.	* 2	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL \$

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 25	\$ <input type="text"/>		x 50	\$ <input type="text"/>
x 100	\$ <input type="text"/>		x 200	\$ <input type="text"/>
+ 180	\$ <input type="text"/>		+ 360	\$ <input type="text"/>
ADDITIONAL FEE TOTAL			TOTAL	\$ <input type="text"/>

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[]	First	-	\$ 60.00
[]	Second	-	\$ 225.00
[]	Third	-	\$ 510.00
[]	Fourth	-	\$ 795.00

Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on .

[] Please charge my Deposit Account No. 02-4035 in the amount of .



[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of .

[] A check in the amount of is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)


By: 
Anne M. Kornbau
Registration No. 25,884



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ARKINSTALL=1

In re Application of:) Conf. No.: 4903
Stephen ARKINSTALL et al)
Appln. No.: 10/070,954) Art Unit: 1624
Filed: July 22, 2002)) Examiner: Brenda L. Coleman
For: PHARMACEUTICALLY ACTIVE) Washington, D.C.
SULFONAMIDE DERIVATIVES) April 11, 2007
)

REPLY: AMENDMENT AND REMARKS

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AF
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Replying to the Office Action mailed January 18,
2007, please amend as follows:

Amendments for the Specifications begin on page 2 of this
paper.

Amendments to the Claims are reflected in the listing of
claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 33 of this paper.